Investigational drugs under study by the United States National Cancer Institute.
D000179:Acrylates / Q000627:therapeutic use; D000477:Alkylating Agents / Q000627:therapeutic use; D003504:Ancitabine / Q000627:therapeutic use; D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001374:Azacitidine / Q000627:therapeutic use; D055598:Chemical Phenomena; D002621:Chemistry; D002865:Chromomycins / Q000627:therapeutic use; D002945:Cisplatin / Q000627:therapeutic use; D004273:DNA, Neoplasm / Q000378:metabolism; D004353:Drug Evaluation, Preclinical; D005047:Etoposide / Q000627:therapeutic use; D006801:Humans; D007069:Ifosfamide / Q000627:therapeutic use; D007939:Leukemia L1210 / Q000188:drug therapy; D051379:Mice; D008938:Mitosis / Q000187:drug effects; D009316:National Institutes of Health (U.S.); D009369:Neoplasms / Q000188:drug therapy*; D009374:Neoplasms, Experimental / Q000188:drug therapy; D011929:Razoxane / Q000627:therapeutic use; D005641:Tegafur / Q000627:therapeutic use; D013713:Teniposide / Q000627:therapeutic use; D014481:United States
D000179:Acrylates; D000477:Alkylating Agents; D000903:Antibiotics, Antineoplastic; D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D002865:Chromomycins; D004273:DNA, Neoplasm; D005641:Tegafur; D011929:Razoxane; D005047:Etoposide; D013713:Teniposide; D003504:Ancitabine; D001374:Azacitidine; D002945:Cisplatin; D007069:Ifosfamide